Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Technology for Paralysis Outpaces Funding

Executive Summary

Among the biggest challenges in medical technology is the search for therapies to help patients regain body function after suffering a paralyzing spinal cord injury. Research in this area is producing some very promising theories and applications that eventually could lead to substantial breakthroughs. Teams of doctors and scientists continue to work diligently in what can be described as a dedicated, niche market, where the driving force is tied to the very basic medical goal of improving these patients' quality of life.

You may also be interested in...



Two Korean Pharmas Vie For Wins In High-Need Gout Space

Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III program for epaminurad, while LG Chem has recently submitting an application for a new Phase III trial with its contender tigulixostat.

US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

340B Dispute Resolution Decisions Subject To Administrative Appeal Under Proposal

US Health and Human Services Department revises approach to 340B administrative dispute resolution process and presiding panel in proposed rule.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel